Abstract:E3 ubiquitin ligases are a large family of proteins that can be classified into three major structurally distinct types: N-end rule E3s, E3s containing the HECT (Homology to E6AP C-Terminus) domain, and E3s with the RING (Really Interesting New Gene) finger, including its derivatives, the U- Box and the PHD (Plant Homeo-Domain). E3 ubiquitin ligases exist as single polypeptide or multimeric complexes. Together with ubiquitin activating enzyme E1 and ubiquitin conjugating enzyme E2, E3 ubiquitin ligases catalyze the ubiquitination of a variety of protein substrates for targeted degradation via the 26S proteasome. E3 ubiqutin ligases, therefore, play an essential role in regulation of many biological processes. Furthermore, E3s are enzymes that determine the specificity of protein substrates; they represent a class of “drugable” targets for pharmaceutical intervention. In this review, I will mainly focus on E3 ubiquitin ligases as potential cancer targets and discuss three of the most promising E3s, Mdm2/Hdm2, IAPs, and SCF, for their target rationales, target validation, and critical issues associated with them. These E3 ligases or their components are over-expressed in many human cancers and their inhibition leads to growth suppression or apoptosis. In addition, I will evaluate two current methodologies available for the high throughput screening for small molecular weight chemical inhibitors of the E3 ubiquitin ligases. Although targeting E3 ubiquitin ligases is still in its infancy, speedy approval of the general proteasome inhibitor, Velcade (bortezomib) by the FDA for the treatment of relapsed and refractory multiple myeloma suggests the promise of specific E3 inhibitors in anti-cancer therapy. Emerging technologies, such as siRNA, will provide a better validation of many E3s. It is anticipated that E3 ubiquitin ligases will represent an important new target platform for future mechanism-driven drug discovery.

Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing Pathways in Neurodegenerative Disorders and Cancer

Targeted Modulation of E3 Ligases Using Engineered Ubiquitin Variants.

UBE3A: Bridging the gap between neurodevelopment, neural function, and neurodegenerative woes

Targeting the Ubiquitin Pathway for Cancer Treatment

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Discovery of E3 Ligase Ligands for Target Protein Degradation

Bivalent Ligands for Protein Degradation in Drug Discovery

Targeting E3 Ubiquitin Ligases for Cancer Therapy

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity

Interlinked destinies: How ubiquitin-proteasome and autophagy systems underpin neurocognitive outcomes

Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment

Targeted protein degradation: expanding the toolbox

Advancing targeted protein degradation for cancer therapy

E3 Ubiquitin Ligases in Protein Quality Control Mechanism

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

E3 ubiquitin ligases as cancer targets and biomarkers.

Progress in Structural and Functional Study of Ubiquitin Ligases

Diverse Roles of the E2/E3 Hybrid Enzyme UBE2O in the Regulation of Protein Ubiquitination, Cellular Functions, and Disease Onset

Post-translational modifications: Regulators of neurodegenerative proteinopathies

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression